^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Trodelvy (sacituzumab govitecan-hziy)

    i
    Other names: IMMU-132, IMMU132, IMMU 132, RS7-SN38, hMN14-SN38, TROP-2-SN-38, hRS7-SN38 antibody drug conjugate, hRS7-SN 38, anti-TROP-2-SN-38 conjugate, anti-TROP-2-SN-38, hRS7-CL2-SN-38, IMMU0132, GS-0132
    Company:
    Gilead
    Drug class:
    Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    2d
    EVOKE-01: Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=603, Active, not recruiting, Gilead Sciences | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    docetaxel • Trodelvy (sacituzumab govitecan-hziy)
    3d
    ADAPT-TN-IV: NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer (clinicaltrials.gov)
    P3, N=765, Not yet recruiting, West German Study Group | Initiation date: Jan 2026 --> Jun 2026
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    6d
    MEDOPP0653: A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LINE THERAPY FOR PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER (The ADJUNCT Study) (2025-521489-80-00)
    P1/2, N=25, Completed, Medica Scientia Innovation Research S.L. | Not yet recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154)
    8d
    ADJUNCT: Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC (clinicaltrials.gov)
    P2, N=0, Withdrawn, MedSIR | N=25 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Yutuo (zimberelimab) • Trodelvy (sacituzumab govitecan-hziy) • domvanalimab (AB154)
    9d
    ASSET: Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, University of Kansas Medical Center | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • PGR positive
    |
    Piqray (alpelisib) • Trodelvy (sacituzumab govitecan-hziy)
    10d
    Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=792, Recruiting, Hoffmann-La Roche | N=56 --> 792
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • atirmociclib (PF-07220060) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)
    10d
    Saci-IO TNBC: Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC (clinicaltrials.gov)
    P2, N=110, Recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    PD-L1 expression • HER-2 negative • PD-L1 negative
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP142) Assay
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    12d
    Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, National Cancer Institute (NCI) | N=120 --> 0 | Trial completion date: Dec 2030 --> Apr 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2029 --> Apr 2026
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    Trodelvy (sacituzumab govitecan-hziy) • Imdelltra (tarlatamab-dlle)
    12d
    Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer (clinicaltrials.gov)
    P2, N=4, Terminated, University of Washington | N=18 --> 4 | Trial completion date: Apr 2027 --> Mar 2026 | Recruiting --> Terminated; Study closed to accrual before meeting accrual goal due to major enrollment challenges based on the very rare disease indication studied and rapid changes in the therapy landscape.
    Enrollment change • Trial completion date • Trial termination
    |
    Trodelvy (sacituzumab govitecan-hziy)
    13d
    Sacituzumab Govitecan as an Effective Strategy for Sensitizing Chemoresistant HNSCC Cells to Senolytic Intervention. (PubMed, bioRxiv)
    Head and neck squamous cell carcinoma (HNSCC) is currently the sixth most prevalent cancer worldwide and is marked by a high tumor relapse frequency due to acquired chemoresistance, requiring alternative strategies to sensitize resistant tumor cell populations to treatment. In vivo studies confirmed that SG treatment followed by ABT-263 limited tumor progression and extended survival without notable toxicity. Thus, SG in combination with senolytic treatment may be an effective strategy for suppressing the growth of cisplatin-resistant HNSCC cells.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    cisplatin • navitoclax (ABT 263) • Trodelvy (sacituzumab govitecan-hziy)
    15d
    Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Fudan University
    New trial • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    carboplatin • Trodelvy (sacituzumab govitecan-hziy)
    15d
    Overcoming ADC resistance in advanced colorectal cancer by dual targeting of TROP2 and PERK to suppress Wnt/β-catenin signaling. (PubMed, Cell Rep Med)
    Furthermore, combining IMMU132 with the PERK inhibitor GSK2606414 yields potent synergy across various CRC preclinical models. Mechanistically, this synergy stems from the enhanced suppression of ER stress and the oncogenic Wnt/β-catenin pathway. Thus, our findings reveal that co-targeting the DNA damage response, the PERK pathway, and the Wnt/β-catenin pathway is a promising strategy to overcome resistance to TROP2-directed antibody-drug conjugates (ADCs) in advanced CRC, providing a rational framework for combination therapies.
    Journal
    |
    ATF4 (Activating Transcription Factor 4)
    |
    Trodelvy (sacituzumab govitecan-hziy) • GSK2606414